ProMACE-cytaBOM方案治疗非霍奇金淋巴瘤的临床疗效观察

Clinical Observation on ProMACE/cytaBOM Regimen as a First-line Treatment in Intermediate and High Grade Malignant Non-Hodgkin's Lymphoma

目的 观察ProMACE cytaBOM方案一线治疗中高度恶性非霍奇金淋巴瘤 (NHL)的近期和远期疗效。 方法 采用ProMACE cytaBOM方案一线治疗 30例中高度恶性非霍奇金淋巴瘤 ,并进行疗效分析。 结果 全组总有效率 (CR +PR )为86 .7% ,完全缓解 (CR)率为 6 6 .7% ,中位缓解期为 9( 3～ 5 8)个月。中位生存时间为 35 ( 1.5～ 6 8)个月 ,全组 1、3、5年生存率分别为5 6 .7%、45 .3%、45 .3%。Ⅱ～Ⅲ期、中度恶性、来源于B细胞、无巨大肿块、LDH正常、化疗≥ 4个周期者的生存率高于Ⅳ期、高度恶性、来源于T细胞、有巨大肿块、LDH不正常、化疗 <4个周期者 ,但无显著性差异 (P >0 .0 5 )。治疗后疗效达到CR者的长期生存率明显高于无效者 (P <0 .0 5 )。主要的不良反应为骨髓抑制和胃肠道反应 ,患者均可耐受。结论 ProMACE cytaBOM方案是治疗中高度NHL的 1个安全有效的化疗方案。

Objective To assess therapeutic effect and toxicity of proMACE/cyta BOM regimen in the treatment of non-Hodgkin's lymphoma(NHL).Methods 30 patients with pathological intermediate and high grade malignant NHL were assigned to receive 2～6 courses of ProMACE/cytaBOM treatment.Results The overall response rate was 86.7%,the complete remission rate was 66.7%.The 1?3?5 years survival rate for the whole group were 56.67%?45.33%?45.33%,respectively.Up to the end of July,2000,16 patients were alive with a median survival of 35 months.The long-term survival rates in patients 0f CR and PR were significantly better than in those of the SD and P (P<0.05).The side effects were tolerable bone marrow suppression and gastric irritation.Conclusion This study indicates that ProMACE/cytaBOM could be a safe and effect regiment for intermediate and high grade maglinant lymphoma.